OGINasdaqPharmaceutical PreparationsFiscal year ends September 30
ORGANIGRAM GLOBAL INC.
Financials through fiscal 2022, year ended Aug 31, 2022Last filing: 40-F on Dec 16, 2025
$0.94+0.02 (+1.73%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2018 to 2022
Gross margin
21.7%
Operating margin
-29.6%
Growth rates
Compound annual growth to fiscal 2022
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +84.2% | +21.9% | – | – | |
| Gross profit | – | -13.3% | – | – |
Returns and balance sheet
5 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2018 | FY2022 | Trend |
|---|---|---|---|---|
| Current ratio | 18.06 | 18.06 | 4.01 | |
| Interest coverage | 3.6× | 3.6× | -100.6× | |
| Inventory turnover | – | – | 2.6× | |
| Capex to revenue | 454.1% | 454.1% | 33.4% | |
| Diluted shares | 32M | 32M | 77M |
Where the cash went
Fiscal 2018 to 2022, five years combined
Organigram Global generated C$157.71M from operations and spent C$302.93M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
C$157.71M
Used
C$302.93M
Capital expenditureC$302.93M100%DividendsC$00%Share buybacksC$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2022 against fiscal 2021
3of 6 tests passed in fiscal 2022. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-C$36.21M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-C$36.21M vs –
- Less leverageLong-term debt to assets fell0.0% → 0.0%
- Better liquidityCurrent ratio rose9.92 → 4.01
- No dilutionShare count did not rise64M → 77M
- Gross margin improvedGross margin up on the prior year-35.87% → 21.65%
- More efficientAsset turnover rose0.18 → 0.26